Industry Insights
-
A Proven Platform For Solid-Phase Oligonucleotide Synthesis
5/25/2022
Facilitating oligonucleotide synthesis with state-of-the-art equipment and process support is critical to maximizing oligo production and achieving consistency at scale.
-
Brexit & The Biopharma Industry: What Happens Next?
4/24/2017
For all the talk of “hard Brexit” and “soft Brexit” and discussion surrounding the post-Brexit relationship between the U.K. and EU, we still don't know much more than we did a year ago.
-
Brexit & The Biopharma Industry: 3 Important Developments To Watch
8/25/2017
There have been considerable updates in the Brexit situation since April 2017, including, the surprising result of the U.K. general election. If anything, news regarding Brexit and the biopharma industry has started to heat up in recent months, and there have been a number of relevant developments that manufacturers must keep their eye on.
-
Maintaining Supply Continuity: 3 Ways To Ease Pharma CMO And CDMO Worries
6/6/2022
Learn practical steps that help pharma contract outsourcers exercise greater control over their supplier-related data, interactions, and processes and put them in a better position to cope with supply continuity challenges as they arise.
-
The Supreme Court’s Upcoming Review Of IPR Constitutionality — A Biopharma Perspective
7/31/2017
IPR provides an adversarial process for challenging patents at the U.S. Patent Office. As of earlier this year, there were over 50 IPR petitions reportedly on file challenging patents relating to the large molecule biopharma space.
-
The Impact Of Early Process Design On Your Supply Chain
10/24/2022
Explore tips to optimize your network supply chain by using a minimal number of unique manifolds to address diverse unit operations requirements.
-
Scale Matters: A Flexible Approach To Demand Uncertainty
Facilities must be designed to ensure a reliable delivery of materials for clinical through commercial manufacturing, including a wide range of bioreactors to suit changing volume needs.
-
Holding The Supply Chain Accountable
3/11/2013
Quality is certainly not new terminology in the pharmaceutical industry. However, I believe it is a term that is sometimes used too loosely within the pharmaceutical time and temperature supply chain. By Jeff Clark, 7P Solutions™, LLC
-
Don’t Neglect This Drug Development Milestone: The Pre-IND Meeting
5/3/2022
The pre-IND meeting takes place when a sponsor presents their planned Phase 1 study design, including their proposed product development plan and regulatory strategy, to the FDA. Think of this as a necessary milestone for a quicker development timeline. This article shares best practices for preparing for the meeting as well as for the meeting itself.
-
Leveraging CDMOs In Pharma’s Drive Toward Net Zero
Environmental considerations in pharmaceutical manufacturing strategies have become increasingly important in the face of additional calls to address pollution and sustainability practices globally.